ReviewRheumatology international2018
The impact of anti-U1-RNP positivity: systemic lupus erythematosus versus mixed connective tissue disease.
Review in Rheumatology international, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 61 citations in OpenAlex.
- Outcomes and Predictors of Treatment Response in Patients With Pure Lupus Membranous Nephropathy.Kidney international reports · 2026Article
- Wernicke's encephalopathy in mixed connective tissue disease triggered by persistent vomiting: a case report and literature review.Rheumatology international · 2026Review
- Old marker, new face: anti-RNP as a sentinel of coronary and peripheral endothelial dysfunction in systemic lupus erythematosus.Lupus science & medicine · 2026Article
- Article
- Clinical characteristics and response to standard-of-care treatment in systemic lupus erythematosus patients with or without anti-ribonucleoprotein (RNP) antibodies: an Australian, multi-centre cohort study.Arthritis research & therapy · 2026Article
- Anti-SMN complex antibodies in paediatric mixed connective tissue disease with interstitial lung disease: clinical and immunological insights.Rheumatology advances in practice · 2026Article
- Spontaneous intermuscular hematoma in mixed connective tissue disease: a case report.Frontiers in surgery · 2026Article
- Transcriptome analysis unveils Th1 cell cycle signature as a distinctive feature of mixed connective tissue disease.Arthritis research & therapy · 2025Article
- Lupus nephritis and U1-RNP-antibodies are associated with low bone mineral density and osteoporosis in patients with systemic lupus erythematosus: baseline findings in a sub-cohort of patients with inflammatory rheumatic diseases.Arthritis research & therapy · 2025Article
- Refractory Acrodermatitis Continua of Hallopeau in a Pediatric Patient: Unveiling Underlying Mixed Connective Tissue Disorder.The Journal of clinical and aesthetic dermatology · 2025Article
- Prognostic insights from symptom clustering analysis in systemic lupus erythematosus.RMD open · 2025Article
- Overlapping Connective Tissue Disease-Polymyositis and Diffuse Systemic Scleroderma: A Case Report.Clinical medicine insights. Arthritis and musculoskeletal disorders · 2025Article
- New advances in genomics and epigenetics in antiphospholipid syndrome.Rheumatology (Oxford, England) · 2024Review
- Doubtful Clinical Value of Subtyping Anti-U1-RNP Antibodies Regarding the RNP-70 kDa Antigen in Sera of Patients with Systemic Lupus Erythematosus.International journal of molecular sciences · 2023Article
- The diagnostic challenge of patients with anti-U1-RNP antibodies.Rheumatology international · 2023Article
- Acute on chronic bilateral renal vein thrombosis in the setting of remission of class V lupus nephritis: A case report and literature review.Clinical nephrology. Case studies · 2023Article
- The Role of Anti-U1 RNP Antibody in Connective Tissue Disease-Associated Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2022Review
- Mixed connective tissue disease after thymectomy in refractory myasthenia gravis.Rheumatology international · 2022Review
- Characterization and clinical significance of biventricular mechanics in patients with systemic lupus erythematosus by 3T cardiovascular magnetic resonance tissue tracking.Quantitative imaging in medicine and surgery · 2022Article
- Prevalence, clinical features, risk factors, and outcomes of SLE patients with aortic aneurysm: a cross-sectional retrospective study in a Chinese single center.Clinical rheumatology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anti-U1-RNP positivity remains mandatory for the mixed connective tissue disease (MCTD) diagnosis, reason for which anti-U1-RNP occurrence in patients with lupus clinical features might determine diagnostic issues. Thus, the prevalence of 25-30% for anti-RNP was reported in John Hopkins and LUMINA lupus cohorts and also 13% prevalence for the anti-U1-RNP in Euro-Lupus cohort. Presence of anti-U1-RNP antibodies in patients fulfilling SLE criteria (but not the MCTD ones) was associated with manifestations such as Raynaud phenomenon, musculoskeletal and lung impairment or nail fold capillaroscopy changes, some clinical features frequently encountered in MCTD patients and only rarely described in lupus population. The use of more specific markers such as 70 kDa anti-U1-RNP or anti-Sm-D was proposed for discriminating between SLE and MCTD. In addition, the IgM serotype of anti-U1-RNP seems more frequently expressed in SLE, while the IgG serotype alone in MCTD. Better acknowledgement of possible clinical involvements in lupus subsets, such as the peculiarities related to the anti-U1-RNP positivity, could provide access to early diagnosis of rather rare but possible severe lupus organ impairments (e.g. pulmonary arterial hypertension).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.